Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS?

Thomas Wurster; Konstantinos Stellos; Michael Haap; Peter Seizer; Tobias Geisler; James Otton; Andreas Indermuehle; Masaki Ishida; Andreas Schuster; Eike Nagel; Meinrad Gawaz; Boris Bigalke

doi:10.1016/j.ijcard.2011.06.082

Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS?

Thomas Wurster, Konstantinos Stellos^*, Michael Haap, Peter Seizer, Tobias Geisler, James Otton, Andreas Indermuehle, Masaki Ishida, Andreas Schuster, Eike Nagel, Meinrad Gawaz, Boris Bigalke

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Background: Acute coronary syndrome (ACS) along with myocardial ischemic injury are the leading causes for chest pain. Platelet surface expression of stromal-cell-derived factor-1 (SDF-1) is enhanced during ischemic events and may play an important role in trafficking hematopoietic progenitor cells for tissue regeneration and neovascularization. This study examined the platelet surface expression of SDF-1 in patients with chest pain.

Methods: We consecutively evaluated 1000 patients, who were admitted to the emergency department with chest pain. Platelet surface expression of GPIb and SDF-1 was determined by two-color whole blood flow cytometry.

Results: Patients with ACS showed significantly enhanced SDF-1 expression on admission compared to patients with other causes such as stable angina pectoris (SAP) and other origin of chest pain (CPO) (ACS vs. SAP/CPO (mean fluorescence intensity (MFI) +/- SD): 39.7 +/- 26.3 vs. SAP: 37.6 +/- 31.5; P=0.045; arterial hypertension: 27.3 +/- 12.7; P=0.003; orthopedic disease: 22.1 +/- 6.5; P=0.014; pulmonary embolism: 26.6 +/- 19.1; P=0.003; Da Costa's syndrome: 22.1 +/- 12.5; P=0.021; inflammatory cardiomyopathy: 19.8 +/- 11.5; P=0.025). Logistic regression analysis showed that surface expression of platelet SDF-1 was significantly associated with ACS (P=0.026), however, the superiority of troponin-I in predicting ACS remains on a high level (P=0.001). Areas under the curve of receiver operating characteristic analysis revealed 0.718 (95% confidence interval (CI): 0.680-0.757) using SDF-1, and 0.795 (95% CI: 0.760-0.829) applying troponin-I baseline serum levels. Patients with enhanced SDF-1 levels (cutoff: MFI >= 27.7) had a 1.4-fold relative risk (95% CI: 1.17-1.52) for ACS.

Conclusions: Platelet SDF-1 surface expression was significantly enhanced in patients with ACS compared to SAP or CPO. Determination of platelet SDF-1 may be useful as an early additional biomarker for cardiovascular risk stratification.

Original language	English
Article number	N/A
Pages (from-to)	111-115
Number of pages	5
Journal	International Journal of Cardiology
Volume	164
Issue number	1
DOIs	https://doi.org/10.1016/j.ijcard.2011.06.082
Publication status	Published - 20 Mar 2013

Keywords

Platelets
SDF-1
Acute Coronary Syndrome
RECEPTOR GLYCOPROTEIN-VI
ACUTE CORONARY SYNDROME
MYOCARDIAL-INFARCTION
PROGENITOR CELLS
CHEST-PAIN
TROPONIN-I
RECRUITMENT
HEART
ATHEROTHROMBOSIS
FACTOR-1-ALPHA

Access to Document

10.1016/j.ijcard.2011.06.082

Cite this

@article{1e181262337840868e3aeb14f2842043,

title = "Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS?",

abstract = "Background: Acute coronary syndrome (ACS) along with myocardial ischemic injury are the leading causes for chest pain. Platelet surface expression of stromal-cell-derived factor-1 (SDF-1) is enhanced during ischemic events and may play an important role in trafficking hematopoietic progenitor cells for tissue regeneration and neovascularization. This study examined the platelet surface expression of SDF-1 in patients with chest pain. Methods: We consecutively evaluated 1000 patients, who were admitted to the emergency department with chest pain. Platelet surface expression of GPIb and SDF-1 was determined by two-color whole blood flow cytometry. Results: Patients with ACS showed significantly enhanced SDF-1 expression on admission compared to patients with other causes such as stable angina pectoris (SAP) and other origin of chest pain (CPO) (ACS vs. SAP/CPO (mean fluorescence intensity (MFI) +/- SD): 39.7 +/- 26.3 vs. SAP: 37.6 +/- 31.5; P=0.045; arterial hypertension: 27.3 +/- 12.7; P=0.003; orthopedic disease: 22.1 +/- 6.5; P=0.014; pulmonary embolism: 26.6 +/- 19.1; P=0.003; Da Costa's syndrome: 22.1 +/- 12.5; P=0.021; inflammatory cardiomyopathy: 19.8 +/- 11.5; P=0.025). Logistic regression analysis showed that surface expression of platelet SDF-1 was significantly associated with ACS (P=0.026), however, the superiority of troponin-I in predicting ACS remains on a high level (P=0.001). Areas under the curve of receiver operating characteristic analysis revealed 0.718 (95% confidence interval (CI): 0.680-0.757) using SDF-1, and 0.795 (95% CI: 0.760-0.829) applying troponin-I baseline serum levels. Patients with enhanced SDF-1 levels (cutoff: MFI >= 27.7) had a 1.4-fold relative risk (95% CI: 1.17-1.52) for ACS. Conclusions: Platelet SDF-1 surface expression was significantly enhanced in patients with ACS compared to SAP or CPO. Determination of platelet SDF-1 may be useful as an early additional biomarker for cardiovascular risk stratification.",

keywords = "Platelets, SDF-1, Acute Coronary Syndrome, RECEPTOR GLYCOPROTEIN-VI, ACUTE CORONARY SYNDROME, MYOCARDIAL-INFARCTION, PROGENITOR CELLS, CHEST-PAIN, TROPONIN-I, RECRUITMENT, HEART, ATHEROTHROMBOSIS, FACTOR-1-ALPHA",

author = "Thomas Wurster and Konstantinos Stellos and Michael Haap and Peter Seizer and Tobias Geisler and James Otton and Andreas Indermuehle and Masaki Ishida and Andreas Schuster and Eike Nagel and Meinrad Gawaz and Boris Bigalke",

year = "2013",

month = mar,

day = "20",

doi = "10.1016/j.ijcard.2011.06.082",

language = "English",

volume = "164",

pages = "111--115",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Platelet expression of stromal-cell-derived factor-1 (SDF-1)

T2 - An indicator for ACS?

AU - Wurster, Thomas

AU - Stellos, Konstantinos

AU - Haap, Michael

AU - Seizer, Peter

AU - Geisler, Tobias

AU - Otton, James

AU - Indermuehle, Andreas

AU - Ishida, Masaki

AU - Schuster, Andreas

AU - Nagel, Eike

AU - Gawaz, Meinrad

AU - Bigalke, Boris

PY - 2013/3/20

Y1 - 2013/3/20

N2 - Background: Acute coronary syndrome (ACS) along with myocardial ischemic injury are the leading causes for chest pain. Platelet surface expression of stromal-cell-derived factor-1 (SDF-1) is enhanced during ischemic events and may play an important role in trafficking hematopoietic progenitor cells for tissue regeneration and neovascularization. This study examined the platelet surface expression of SDF-1 in patients with chest pain. Methods: We consecutively evaluated 1000 patients, who were admitted to the emergency department with chest pain. Platelet surface expression of GPIb and SDF-1 was determined by two-color whole blood flow cytometry. Results: Patients with ACS showed significantly enhanced SDF-1 expression on admission compared to patients with other causes such as stable angina pectoris (SAP) and other origin of chest pain (CPO) (ACS vs. SAP/CPO (mean fluorescence intensity (MFI) +/- SD): 39.7 +/- 26.3 vs. SAP: 37.6 +/- 31.5; P=0.045; arterial hypertension: 27.3 +/- 12.7; P=0.003; orthopedic disease: 22.1 +/- 6.5; P=0.014; pulmonary embolism: 26.6 +/- 19.1; P=0.003; Da Costa's syndrome: 22.1 +/- 12.5; P=0.021; inflammatory cardiomyopathy: 19.8 +/- 11.5; P=0.025). Logistic regression analysis showed that surface expression of platelet SDF-1 was significantly associated with ACS (P=0.026), however, the superiority of troponin-I in predicting ACS remains on a high level (P=0.001). Areas under the curve of receiver operating characteristic analysis revealed 0.718 (95% confidence interval (CI): 0.680-0.757) using SDF-1, and 0.795 (95% CI: 0.760-0.829) applying troponin-I baseline serum levels. Patients with enhanced SDF-1 levels (cutoff: MFI >= 27.7) had a 1.4-fold relative risk (95% CI: 1.17-1.52) for ACS. Conclusions: Platelet SDF-1 surface expression was significantly enhanced in patients with ACS compared to SAP or CPO. Determination of platelet SDF-1 may be useful as an early additional biomarker for cardiovascular risk stratification.

AB - Background: Acute coronary syndrome (ACS) along with myocardial ischemic injury are the leading causes for chest pain. Platelet surface expression of stromal-cell-derived factor-1 (SDF-1) is enhanced during ischemic events and may play an important role in trafficking hematopoietic progenitor cells for tissue regeneration and neovascularization. This study examined the platelet surface expression of SDF-1 in patients with chest pain. Methods: We consecutively evaluated 1000 patients, who were admitted to the emergency department with chest pain. Platelet surface expression of GPIb and SDF-1 was determined by two-color whole blood flow cytometry. Results: Patients with ACS showed significantly enhanced SDF-1 expression on admission compared to patients with other causes such as stable angina pectoris (SAP) and other origin of chest pain (CPO) (ACS vs. SAP/CPO (mean fluorescence intensity (MFI) +/- SD): 39.7 +/- 26.3 vs. SAP: 37.6 +/- 31.5; P=0.045; arterial hypertension: 27.3 +/- 12.7; P=0.003; orthopedic disease: 22.1 +/- 6.5; P=0.014; pulmonary embolism: 26.6 +/- 19.1; P=0.003; Da Costa's syndrome: 22.1 +/- 12.5; P=0.021; inflammatory cardiomyopathy: 19.8 +/- 11.5; P=0.025). Logistic regression analysis showed that surface expression of platelet SDF-1 was significantly associated with ACS (P=0.026), however, the superiority of troponin-I in predicting ACS remains on a high level (P=0.001). Areas under the curve of receiver operating characteristic analysis revealed 0.718 (95% confidence interval (CI): 0.680-0.757) using SDF-1, and 0.795 (95% CI: 0.760-0.829) applying troponin-I baseline serum levels. Patients with enhanced SDF-1 levels (cutoff: MFI >= 27.7) had a 1.4-fold relative risk (95% CI: 1.17-1.52) for ACS. Conclusions: Platelet SDF-1 surface expression was significantly enhanced in patients with ACS compared to SAP or CPO. Determination of platelet SDF-1 may be useful as an early additional biomarker for cardiovascular risk stratification.

KW - Platelets

KW - SDF-1

KW - Acute Coronary Syndrome

KW - RECEPTOR GLYCOPROTEIN-VI

KW - ACUTE CORONARY SYNDROME

KW - MYOCARDIAL-INFARCTION

KW - PROGENITOR CELLS

KW - CHEST-PAIN

KW - TROPONIN-I

KW - RECRUITMENT

KW - HEART

KW - ATHEROTHROMBOSIS

KW - FACTOR-1-ALPHA

U2 - 10.1016/j.ijcard.2011.06.082

DO - 10.1016/j.ijcard.2011.06.082

M3 - Article

SN - 0167-5273

VL - 164

SP - 111

EP - 115

JO - International Journal of Cardiology

JF - International Journal of Cardiology

IS - 1

M1 - N/A

ER -

Platelet expression of stromal-cell-derived factor-1 (SDF-1): An indicator for ACS?

Abstract

Keywords

Access to Document

Fingerprint

Cite this